Abstract
Clinical impact of depth of response on 3 months after starting chemotherapy and cumulative dose of bortezomib on survival in elderly patients with multiple myeloma who treated with bortezomib combined melphalan plus prednisolone; How to improve survival rates by longer duration of treatment and early deeper response
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have